Catalent (CTLT) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Catalent, Inc. Reports Second Quarter Fiscal Year 2017 Results
February 6, 2017 4:15 PM ESTQ2'17 revenue $483.7 million increased 6% as-reported, or 10% in constant currency from the prior year period. Q2'17 YTD revenue $925.9 million increased 5% as-reported, or 9% in constant currency from the prior year period. Announced the acquisition of Accucaps, a Canadian developer and manufacturer of over-the-counter (OTC) and prescription softgel products. Issued 380 million, 4.75% coupon, Euro notes with proceeds used to pay down debt and fund acquisitions; simultaneous re-price of our USD (50 bps rate reduction) and EUR (75 bps rate reduction) Term Loans.... More
